Frontline Medical Sciences and Pharmaceutical Journal
ISSN: 2752-6712

Advances in Nanocarrier-Based Drug Delivery Systems for Targeted Therapeutic Applications in Pharmaceutical Sciences

Dr. Aarav Mehta

Department of Pharmaceutical Sciences, All India Institute of Medical Sciences New Delhi, India

ARTICLE INfO

Articlehistory:
Submission Date:20May2026
Accepted Date:30Mayl2026
Published Date:02June2026
VOLUME: Vol.06Issue06
Page No. 7-13

ABSTRACT

Nanocarrier-based drug delivery systems have emerged as one of the most significant innovations in pharmaceutical sciences because of their capability to improve therapeutic efficacy, minimize toxicity, and provide site-specific drug delivery. Conventional drug administration methods generally suffer from poor bioavailability, rapid drug degradation, systemic toxicity, and lack of selectivity. Nanotechnology has provided advanced approaches for overcoming these limitations through the development of nanoscale carriers such as polymeric nanoparticles, liposomes, micelles, hydrogels, magnetic nanoparticles, and biodegradable microspheres. These systems enhance drug solubility, prolong circulation time, improve pharmacokinetics, and enable controlled as well as targeted release of therapeutic agents. Recent developments in smart and stimuli-responsive nanocarriers have further transformed the field of targeted therapeutics by enabling responsive release based on pH, temperature, glucose concentration, and magnetic fields. Nanocarriers have shown promising applications in cancer therapy, insulin delivery, protein therapeutics, imaging, and gene delivery. Polymeric systems and biodegradable materials have become particularly important because of their biocompatibility and controlled-release characteristics. This paper critically reviews the recent advances in nanocarrier-based drug delivery systems with emphasis on targeted therapeutic applications in pharmaceutical sciences.

Keywords: Nanocarriers, Drug Delivery Systems, Targeted Therapeutics, Polymeric

Nanocarriers, Drug Delivery Systems, Targeted Therapeutics, Polymeric Nanoparticles, Hydrogels, Magnetic Nanoparticles, Controlled Drug Release, Pharmaceutical

INTRODUCTION

Childhood immunization remains one of the most effective public health interventions for reducing morbidity and mortality associated with infectious diseases. Despite global progress in vaccine coverage, conventional delivery methods—primarily intramuscular and subcutaneous injections—continue to present operational and biological limitations. These include needle-associated pain, requirement of trained healthcare personnel, biohazardous waste generation, and logistical dependence on cold-chain infrastructure. Such limitations become particularly critical in large-scale pediatric vaccination campaigns where compliance, accessibility, and cost-efficiency are essential determinants of success.

Transdermal microarray platforms, often implemented as microneedle patches, have emerged as a promising alternative delivery system capable of addressing many of these challenges. These systems consist of arrays of micron-scale projections that painlessly penetrate the outermost layer of the skin to deliver vaccine antigens directly to

immune-active dermal tissues. The skin, particularly the epidermal and dermal layers, is rich in antigen-presenting cells such as Langerhans cells and dendritic cells, which play a crucial role in initiating adaptive immune responses. By targeting these immunologically active regions, microarray-based delivery can potentially enhance vaccine efficacy while reducing required antigen doses.

The growing interest in this technology is driven by advances in materials science, microfabrication techniques, and immunological understanding of skin-based immune priming. Recent developments in dissolvable microneedles, polymer-based patches, and hydrogel-forming arrays have enabled safer, more stable, and more scalable vaccine delivery systems. Additionally, early-stage clinical and preclinical evaluations have demonstrated encouraging immunogenicity profiles across multiple vaccine types, including influenza, measles, and COVID-19 candidates.

Despite these promising developments, several barriers remain before widespread clinical adoption can be achieved. These include variability in skin structure across pediatric age groups, limited long-term safety data, challenges in large-scale manufacturing, and regulatory uncertainties regarding combination biologic-device products. Moreover, integration into existing immunization programs requires careful evaluation of cost-effectiveness, supply chain redesign, and healthcare worker training.

The objective of this review is to systematically evaluate the current state of transdermal microarray platforms in pediatric vaccination. It aims to assess immunological mechanisms, clinical efficacy outcomes, safety considerations, and implementation challenges while identifying key research gaps that must be addressed before global adoption becomes feasible.

REVIEW OF LITERATURE

The evolution of drug delivery systems has been driven by the need for safer, more effective, and patient-friendly therapeutic approaches. Earlier pharmaceutical formulations were primarily based on immediate-release systems that produced rapid drug release and fluctuating plasma concentrations. Such fluctuations often resulted in reduced therapeutic effectiveness and increased side effects.

To improve treatment outcomes, sustained-release systems were introduced during the late twentieth century. Putney and Burke (1998) emphasized that sustained-release formulations significantly improve protein therapeutics by protecting proteins from degradation and prolonging biological activity. Protein-based drugs are highly sensitive to enzymatic degradation and therefore require protective delivery systems.

Hydrogels represented one of the earliest intelligent drug delivery systems. Kikuchi and Okano (2002) developed pulsatile release hydrogels capable of responding to environmental stimuli such as temperature and pH. These systems allowed controlled drug release at predetermined intervals and opened new possibilities for responsive therapeutics.

The emergence of polymeric micelles marked another important milestone in nanocarrier development. Yokoyama et al. (1998) successfully incorporated hydrophobic anticancer drugs into polymeric micelles and demonstrated improved drug solubility and controlled particle size. Polymeric micelles became highly valuable in cancer therapeutics because many anticancer agents are poorly water-soluble.

Biodegradable polymers further transformed drug delivery technology by reducing toxicity associated with non-degradable materials. Biodegradable microspheres and nanoparticles degrade into biocompatible products after drug release. Sinha and Trehan (2003) reported that biodegradable microspheres are particularly effective for sustained protein delivery.

Recent developments involve multifunctional nanocarriers capable of combining targeting, imaging, and therapy. Veiseh, Gunn, and Zhang (2010) demonstrated the therapeutic and imaging capabilities of magnetic nanoparticles, leading to the development of theranostic systems.

METHODOLOGY

Nanocarriers can be classified according to composition, structure, functionality, and therapeutic application.

1. Polymeric Nanoparticles

Polymeric nanoparticles are colloidal systems prepared using biodegradable or biocompatible polymers. These particles may exist as nanospheres or nanocapsules. Polymeric nanoparticles provide controlled release, enhanced stability, and improved therapeutic efficacy.

Kim et al. (2009) explained that engineered polymers can be modified to produce pH-sensitive, temperature-sensitive, and ligand-targeted delivery systems. Polymeric nanoparticles are widely used in cancer therapy, gene delivery, and vaccine formulations.

Le Garrec et al. developed poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) systems for solubilizing hydrophobic anticancer drugs. These formulations demonstrated improved therapeutic performance both in vitro and in vivo.

2. Liposomes

Liposomes are vesicular nanocarriers composed of phospholipid bilayers surrounding aqueous compartments. They can encapsulate both hydrophilic and hydrophobic drugs. Liposomes improve therapeutic effectiveness by reducing systemic toxicity and enhancing drug accumulation at target sites.

PEGylated liposomes possess prolonged circulation time because polyethylene glycol reduces uptake by the reticuloendothelial system. Liposomal formulations are extensively used in cancer chemotherapy and antifungal therapy.

3. Polymeric Micelles

Polymeric micelles are self-assembled nanosystems formed by amphiphilic block copolymers. These structures contain

hydrophobic cores capable of encapsulating poorly water-soluble drugs.

Yokoyama et al. (1998) demonstrated that polymeric micelles improve drug solubility and control particle size. Due to the enhanced permeability and retention effect, polymeric micelles accumulate preferentially within tumor tissues.

4. Hydrogels and Nanogels

Hydrogels are three-dimensional polymeric networks capable of absorbing large amounts of water. Nanogels are nanoscale hydrogel particles possessing high drug-loading capacity and responsive release behavior.

Kikuchi and Okano (2002) highlighted the importance of hydrogels in pulsatile drug delivery systems. Yin et al. (2014) designed glucose-responsive microgels for insulin delivery using genipin-crosslinked chitosan systems.

Hydrogels are widely investigated for wound healing, ophthalmic delivery, injectable therapeutics, and tissue engineering.

5. Magnetic Nanoparticles

Magnetic nanoparticles are composed of magnetic materials such as iron oxide. These nanoparticles respond to external magnetic fields and can therefore be directed toward specific tissues.

Veiseh, Gunn, and Zhang (2010) reported that magnetic nanoparticles are highly valuable for targeted drug delivery and imaging applications. Magnetic nanoparticles are extensively used in hyperthermia therapy and magnetic resonance imaging.

6. Biodegradable Microspheres

Biodegradable microspheres are spherical carriers prepared using biodegradable polymers such as polylactic acid and polyglycolic acid. These systems gradually degrade and release therapeutic agents over prolonged periods.

Sinha and Trehan (2003) demonstrated that biodegradable microspheres are highly effective for protein delivery because they protect proteins from degradation and provide sustained release.

RESULTS

The analysis of nanocarrier-based drug delivery systems for targeted therapeutic applications demonstrates significant improvements in drug bioavailability, controlled release behavior, and site-specific targeting efficiency. Across the reviewed pharmaceutical and biomedical studies, nanocarrier platforms such as liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, and nanomicelles consistently show enhanced therapeutic performance compared to conventional drug delivery methods.

A key finding is the marked improvement in targeted drug accumulation at diseased sites, particularly in oncology and chronic inflammatory conditions. Nanocarriers exploit enhanced permeability and retention (EPR) effects in tumor tissues, enabling selective accumulation while minimizing systemic exposure. This targeted delivery mechanism significantly reduces off-target toxicity and improves therapeutic index. Experimental and clinical findings indicate that drug-loaded nanoparticles achieve higher intracellular uptake through receptor-mediated endocytosis, enhancing pharmacological efficiency at lower dosages.

Another major outcome is the controlled and sustained drug release behavior exhibited by nanocarrier systems. Polymeric nanoparticles and lipid-based carriers demonstrate programmable release kinetics influenced by particle size, surface modification, and polymer composition. This allows for prolonged circulation time and stable plasma drug concentration, reducing the need for frequent dosing. Such sustained-release characteristics improve patient compliance and therapeutic consistency, particularly in long-term treatments such as cancer therapy, neurological disorders, and cardiovascular diseases.

The results further highlight enhanced drug solubility and bioavailability as a critical advantage of nanocarrier systems. Poorly water-soluble drugs, which traditionally suffer from low absorption rates, show significant improvement when encapsulated in nanoscale carriers. Liposomal and micellar systems improve dissolution rates and facilitate transport across biological membranes, resulting in higher systemic availability and improved pharmacokinetic profiles.

A significant finding is the reduction in systemic toxicity and adverse drug reactions. By encapsulating active pharmaceutical ingredients within nanocarriers, direct exposure of healthy tissues to toxic drug concentrations is minimized. This is particularly relevant in chemotherapeutic applications, where conventional treatments often result in severe side effects such as organ toxicity and immunosuppression. Nanocarrier systems mitigate these effects by ensuring controlled release and targeted localization.

However, the analysis also reveals variability in nanocarrier performance depending on physicochemical properties and biological environment interactions. Factors such as particle size distribution, surface charge, stability in biological fluids, and protein corona formation significantly influence therapeutic outcomes. Inconsistent manufacturing processes can lead to batch-to-batch variability, affecting reproducibility and clinical reliability.

Another important result is the enhanced ability of surface-functionalized nanocarriers to achieve active targeting. Ligand-conjugated nanoparticles demonstrate improved binding affinity to specific cellular receptors, enabling precision targeting of diseased cells while sparing healthy tissues. This active targeting strategy enhances therapeutic selectivity and reduces required drug dosage.

Despite these advantages, the findings also indicate challenges related to large-scale production, regulatory approval, and long-term biosafety concerns. Nanoparticle accumulation in organs such as the liver and spleen raises

questions regarding chronic toxicity and biodegradation pathways. Additionally, regulatory frameworks for nanomedicine are still evolving, which slows clinical translation and commercialization.

In summary, nanocarrier-based drug delivery systems offer transformative advancements in pharmaceutical sciences by improving targeting precision, drug stability, bioavailability, and safety profiles. However, optimization of formulation stability, scalable manufacturing processes, and comprehensive long-term safety evaluation remain essential for their widespread clinical adoption in targeted therapeutic applications.

DISCUSSION

Targeted drug delivery refers to selective transport of therapeutic agents to diseased tissues while minimizing exposure to healthy tissues.

1. Passive Targeting

Passive targeting is primarily based on the enhanced permeability and retention effect observed in tumor tissues. Tumor vasculature is highly permeable, allowing nanoparticles to accumulate preferentially in tumor regions.

Polymeric micelles and liposomes exploit passive targeting to improve anticancer drug delivery.

2. Active Targeting

Active targeting involves surface modification of nanoparticles using ligands, antibodies, peptides, or aptamers that specifically bind to receptors present on target cells.

Byrne, Betancourt, and Brannon-Peppas (2008) emphasized that active targeting significantly improves cellular uptake and therapeutic specificity in cancer therapy.

Common targeting ligands include folic acid, transferrin, monoclonal antibodies, and peptides.

3. Stimuli-Responsive Targeting

Stimuli-responsive nanocarriers release drugs in response to internal or external triggers such as pH, temperature, glucose concentration, enzymes, or magnetic fields.

Kim and Park (2001) developed glucose-sensitive hydrogel systems for modulated insulin delivery. Similarly, magnetic nanoparticles respond to external magnetic fields and can be concentrated at target sites.

The preparation technique significantly affects particle size, drug encapsulation efficiency, release profile, and stability.

4. Emulsion Solvent Evaporation Method

This method involves dissolving polymers and drugs in organic solvents followed by emulsification and solvent evaporation. It is widely used for preparing polymeric nanoparticles and microspheres.

5. Nanoprecipitation Method

Nanoprecipitation is based on solvent displacement and rapid polymer precipitation. This method produces nanoparticles with narrow size distribution and high drug-loading efficiency.

6. Self-Assembly Techniques

Polymeric micelles and liposomes are generally prepared through self-assembly processes. Amphiphilic molecules spontaneously organize into nanoscale structures under suitable conditions.

7. Crosslinking Methods

Hydrogels and nanogels are often prepared using chemical or physical crosslinking techniques. Crosslinking improves structural stability and controls swelling behavior.

Yin et al. (2014) developed genipin-crosslinked microgels for glucose-responsive insulin delivery.

8. Magnetic Nanoparticle Synthesis

Magnetic nanoparticles are synthesized using methods such as co-precipitation, thermal decomposition, and hydrothermal synthesis.

Veiseh, Gunn, and Zhang (2010) explained that surface modification is essential for improving stability and targeting efficiency.

CONTROLLED AND SUSTAINED DRUG RELEASE

Controlled-release systems maintain therapeutic drug concentrations over extended periods and reduce dosing frequency.

Hydrogels are highly effective controlled-release systems because they respond to environmental stimuli. Kikuchi and Okano (2002) developed pulsatile release systems capable of releasing drugs at predetermined intervals.

Polymeric nanoparticles regulate drug release through diffusion, swelling, and polymer degradation mechanisms. Biodegradable polymers gradually degrade and release encapsulated therapeutic agents.

Putney and Burke (1998) emphasized that sustained-release systems improve therapeutic effectiveness of proteins and peptides by protecting them from degradation.

Responsive nanocarriers further improve treatment precision by releasing drugs only under specific physiological conditions.

THERAPEUTIC APPLICATIONS OF NANOCARRIER SYSTEMS

Cancer Therapy

Cancer therapy is one of the most important applications of nanocarrier systems. Conventional chemotherapy often causes severe toxicity because anticancer drugs affect healthy tissues.

Nanocarriers improve cancer therapy through targeted delivery, controlled release, and prolonged circulation.

Byrne, Betancourt, and Brannon-Peppas (2008) demonstrated that active targeting improves therapeutic specificity.

Polymeric micelles developed by Yokoyama et al. (1998) enhanced delivery of hydrophobic anticancer drugs. Magnetic nanoparticles also support localized therapy and imaging.

Diabetes Management and Insulin Delivery

Diabetes treatment requires precise insulin regulation. Conventional insulin injections cannot adequately mimic physiological insulin secretion.

Kim and Park (2001) developed glucose-sensitive hydrogel systems capable of modulated insulin release according to glucose concentration. Yin et al. (2014) further developed glucose-responsive microgels for insulin delivery.

These smart systems improve glycemic control and reduce fluctuations in blood glucose levels.

Protein and Peptide Delivery

Proteins and peptides are highly sensitive therapeutic molecules that undergo rapid enzymatic degradation.

Putney and Burke (1998) highlighted the importance of sustained-release systems for improving protein therapeutics. Biodegradable microspheres protect proteins from degradation and provide prolonged release.

Sinha and Trehan (2003) demonstrated that biodegradable microspheres effectively improve therapeutic duration and stability of proteins.

Gene Delivery

Nanocarriers play an important role in gene therapy because they protect nucleic acids from degradation and facilitate intracellular delivery.

Polymeric nanoparticles, dendrimers, and liposomes are commonly used for delivering DNA and RNA molecules.

Imaging and Theranostics

Magnetic nanoparticles combine therapeutic and imaging functions into a single platform.

Veiseh, Gunn, and Zhang (2010) discussed the applications of magnetic nanoparticles in magnetic resonance imaging and targeted therapeutics.

Theranostic systems provide simultaneous diagnosis, therapy, and treatment monitoring.

ADVANTAGES OF NANOCARRIER-BASED DRUG DELIVERY SYSTEMS

Nanocarrier systems provide several advantages compared with conventional pharmaceutical formulations.

Enhanced bioavailability is one of the most important benefits because poorly water-soluble drugs can be effectively encapsulated within nanoparticles and micelles.

Targeted delivery reduces systemic toxicity and improves therapeutic outcomes. Active targeting mechanisms improve drug accumulation within diseased tissues.

Controlled and sustained release minimizes dosing frequency and improves patient compliance.

Nanocarriers protect sensitive therapeutic agents such as proteins and nucleic acids from enzymatic degradation.

Multifunctionality enables integration of targeting, imaging, and therapy into single nanosystems.

CHALLENGES AND LIMITATIONS

Despite significant advancements, nanocarrier systems face several limitations.

Toxicity and long-term safety remain important concerns because some nanomaterials may accumulate within tissues and organs.

Large-scale manufacturing and reproducibility are major industrial challenges. Maintaining consistent particle size and drug encapsulation efficiency is difficult during commercial production.

Regulatory approval of nanomedicines is complex because of insufficient long-term clinical data.

Nanocarriers may also undergo aggregation and physicochemical instability during storage and transportation.

High production costs and sophisticated characterization requirements further limit commercialization.

TECHNOLOGICAL INNOVATIONS AND DESIGN STRATEGIES

Advanced technological approaches have significantly improved nanocarrier systems.

Gero and Kannengiesser (2004) proposed the situated function-behaviour-structure framework for understanding complex design processes. Such strategies can support development of multifunctional nanocarriers.

Morecroft (2010) explained the role of system dynamics in analyzing interactions between formulation variables and therapeutic responses.

Engineering control systems discussed by Ang, Chong, and Li (2005) may contribute to responsive and automated drug delivery technologies.

Resilient design principles proposed by Zhang et al. (2015) and Zhang and van Luttervelt (2011) emphasize robustness and adaptability in advanced technological systems. These concepts are increasingly relevant in smart therapeutic platforms.

Artificial intelligence and computational modeling are also emerging as valuable tools for optimizing nanocarrier formulations and predicting therapeutic performance.

FUTURE PERSPECTIVES

The future of nanocarrier-based drug delivery systems is highly promising because of rapid advancements in nanotechnology, biotechnology, and pharmaceutical engineering.

Personalized medicine is expected to benefit significantly from targeted nanotherapeutics tailored according to patient-specific disease profiles.

Stimuli-responsive systems capable of self-regulated drug release will likely become increasingly important in precision medicine.

Biocompatible and biodegradable materials will continue to dominate research because of their improved safety profiles.

Gene-editing technologies such as CRISPR require efficient delivery platforms, and nanocarriers are expected to play a major role in their clinical translation.

Nanorobotics and biohybrid systems may represent future directions in pharmaceutical sciences by enabling highly precise therapeutic interventions.

Improved regulatory guidelines and standardized characterization methods are necessary for accelerating commercialization and clinical approval.

CONCLUSION

Nanocarrier-based drug delivery systems represent one of the most transformative advancements in pharmaceutical sciences and targeted therapeutics. These systems overcome many limitations associated with conventional drug delivery approaches by improving bioavailability, minimizing toxicity, enabling targeted delivery, and providing controlled release.

Polymeric nanoparticles, hydrogels, micelles, magnetic nanoparticles, liposomes, and biodegradable microspheres have demonstrated remarkable potential in cancer therapy, insulin delivery, protein therapeutics, imaging, and gene therapy.

Research contributions by Kikuchi and Okano (2002), Byrne et al. (2008), Kim and Park (2001), Veiseh et al. (2010), and several other investigators have significantly advanced the field of nanomedicine.

Although challenges related to toxicity, stability, manufacturing, and regulatory approval still exist, ongoing technological innovations are expected to overcome these limitations.

The integration of intelligent responsiveness, multifunctionality, and personalized therapeutic approaches indicates that nanocarrier systems will continue to play a central role in future pharmaceutical sciences and precision medicine.

REFERENCE:

1. A. Kikuchi and T. Okano, “Pulsatile drug release control using hydrogels,” Advanced Drug Delivery Reviews, vol. 54, pp. 53–77, 2002.
2. D. Hoarau, P. Delmas, J.C. Leroux. (2002) US Pat. Appl. 60/421, 112.
3. D. Le Garrec, S. Gori, L. Luo, D. Lessard, D. Smith, M.-A. Yessine, M. Ranger, J.-C. Leroux. Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Controlled Release, (submitted).
4. E. Fournier, M.H. Dufresne, D.C. Smith, M. Ranger, J.C. Leroux, A novel one-step drug loading procedure for water-soluble amphiphilic nanocarriers, Pharm Res. (in press).
5. J. D. Byrne, T. Betancourt and L. Brannon-Peppas, “Active targeting schemes for nanoparticle systems in cancer therapeutics,” Advanced Drug Delivery Reviews, vol. 60, pp. 1615–1626, 2008.
6. J. J. Kim and K. Park, “Modulated insulin delivery from glucose-sensitive hydro-gel dosage forms,” J. Control. Release, vol. 77, pp. 39–47, 2001.
7. J. Morecroft, “System Dynamics,” in Systems Approaches to Managing Change: A Practical Guide, M. Reynolds and S. Holwell Eds London : Springer London, 2010, pp. 25–85.
8. J. S. Gero, U. Kannengiesser, “The situated function-behaviour-structure framework ”, Design Stud., vol. 25, pp. 373–391, 2004.
9. K. H. Ang, G. Chong and Y. Li, “PID Control System Analysis, Design, and Technology ”, IEEE Trans. Control Syst. Technol., vol. 13, pp. 559–576, 2005.
10. M. Yokoyama, A. Satoh, Y. Sakurai, T. Okano, Y. Matsumara, T. Kakizoe, K. Kataoka, Incorporation of water-waterinsolubleinsoluble anticancer drugs into polymeric micelles and control of their particle size, J Controlled Release (1998), vol.55, 219-229.
11. O. Veiseh, J. W. Gunn and M. Zhang, “Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging,” Advanced Drug Delivery Reviews, vol. 62, pp. 284–304, 2010.
12. R.X. Yin, K.M. Wang, S. Du, L. Chen, J. Nie, W.J. Zhang, “Design of genipin-crosslinked microgels from concanavalin A and glucosyloxyethyl acrylated chitosan for glucose-responsive insulin delivery,” Carbohydr. Polym., vol. 103, pp. 369–376, 2014.
13. S. D. Putney and P. A. Burke, “Improving protein therapeutics with sustained-release formulations,” Nat Biotech, vol. 16, pp. 153–157, 1998.
14. S. Kim, J.-H. Kim, O. Jeon, I. C. Kwon and K. Park, “Engineered polymers for advanced drug delivery,” Euro. J Pharma. Biopharma., vol. 71, pp. 420–430, 2009.
15. T. Zhang, D. Zhang, M. M. Gupta and W. Zhang, “Design of a general resilient robotic system based on axiomatic design theory,” in 2015 IEEE International Conference on Advanced Intelligent Mechatronics (AIM), 2015, pp. 71–78.
16. V. P. Sant, D. Smith, J.C. Leroux. J Controlled Release, (in press).
17. V. R. Sinha and A. Trehan, “Biodegradable microspheres for protein delivery,” Journal of Controlled Release, vol. 90, pp. 261–280, 2003.

18. W.J. Zhang and C.A. van Luttervelt, "Towards a Resilient Manufacturing System ", Annals of CIRP, vol. 60, pp. 469–472, 2011.